Loss of ARHGAP40 expression in basal cell carcinoma via CpG island hypermethylation.
ARHGAP40
BCC
expression
hypermethylation
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
24
09
2023
received:
14
06
2023
accepted:
04
10
2023
medline:
4
12
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Basal cell carcinoma (BCC) is the most common malignant tumour arising from the basal cells of the epidermis or follicular structures. The aetiology of BCC is a multifactorial combination of genotype, phenotype and environmental factors. The pathogenesis of BCC remains unclear, with diverse and complex signalling pathways involved. ARHGAP40 is a Rho GTPase-activating protein (RhoGAP). Rho GTPases play a crucial role in the formation and progression of numerous cancers. The expression levels and roles of ARHGAP40 in BCC have not been explored. Here, ARHGAP40 expression was detected in a set of formalin-fixed, paraffin-embedded (FFPE) samples of basal cell carcinoma, paracancerous normal skin and benign skin lesions. The epigenetic mechanism that downregulates ARHGAP40 in basal cell carcinoma was investigated. We found that ARHGAP40 is expressed in normal basal cells and most benign skin lesions but lost in most basal cell carcinomas. We detected CpG island hypermethylation at the promoter-associated region of ARHGAP40. Our data suggest that ARHGAP40 is downregulated in BCC due to hypermethylation. ARHGAP40 protein is a potential novel biomarker for distinguishing trichoblastoma from BCC. This report is preliminary, and extensive research into the role of ARHGAP40 in BCC carcinogenesis and its potential as a treatment target is required in the future.
Substances chimiques
GTPase-Activating Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2094-2101Subventions
Organisme : 16th batch of six talent peak projects in Jiangsu Province
ID : WSN-043
Organisme : Jiangsu Province's fifth and sixth phase 333 high-level talent project
ID : 2022-3-28-020
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262-2269.
Chen OM, Kim K, Steele C, et al. Advances in management and therapeutics of cutaneous basal cell carcinoma. Cancers (Basel). 2022;14:14.
Dika E, Scarfi F, Ferracin M, et al. Basal cell carcinoma: a comprehensive review. Int J Mol Sci. 2020;21:5572.
Kasumagic-Halilovic E, Hasic M, Ovcina-Kurtovic N. A clinical study of basal cell carcinoma. Med Arch. 2019;73:394-398.
Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48:398-406.
Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019;33:13-24.
Jiang Y, Liu S, Chen X, Cao Y, Tao Y. Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. Biochim Biophys Acta. 2013;1835:155-163.
Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer. 2012;106:248-253.
Eismann L, von Walter P, Jung A, et al. Methylation status of various gene loci in localized prostate cancer: novel biomarkers for diagnostics and biochemical recurrence. Urol Oncol. 2023;41:325.e1-325.e8.
Irie T, Yamada H, Takeuchi C, et al. The methylation level of a single cancer risk marker gene reflects methylation burden in gastric mucosa. Gastric Cancer. 2023;26:667-676.
Li X, Cai D, Huang Y, et al. Aberrant methylation in neurofunctional gene serves as a hallmark of tumorigenesis and progression in colorectal cancer. BMC Cancer. 2023;23:315.
Brinkhuizen T, van Geel M, Denil SL, et al. Locally advanced basal cell carcinoma has a distinct methylation and transcriptomic profile. Exp Dermatol. 2016;25:316-318.
Heitzer E, Bambach I, Dandachi N, Horn M, Wolf P. PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches. Exp Dermatol. 2010;19:926-928.
Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H. Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene. 2003;22:5519-5524.
Liu J, Yu N, Feng X, et al. Loss of EphA7 expression in basal cell carcinoma by hypermethylation of CpG islands in the promoter region. Anal Cell Pathol (Amst). 2022;2022:4220786.
Mosaddeghzadeh N, Ahmadian MR. The RHO family GTPases: mechanisms of regulation and signaling. Cells. 2021;7:10.
Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 2003;13:13-22.
Chang J, Tran DC, Zhu GA, et al. Initial in vitro functional characterization of serum exosomal microRNAs from patients with metastatic basal cell carcinoma. Br J Dermatol. 2017;177:e187-e190.
Sand M, Skrygan M, Sand D, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167:847-855.
Wei HP, Zhan S, Zhu QA, et al. Genome-wide expression difference of MicroRNAs in basal cell carcinoma. J Immunol Res. 2021;2021:7223500.
Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2011;6:388-394.
Nandakumar V, Vaid M, Tollefsbol TO, Katiyar SK. Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice. Carcinogenesis. 2011;32:597-604.
Luo N, Guo J, Chen L, Yang W, Qu X, Cheng Z. ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis. 2016;7:e2157.
Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ. The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells. Oncol Lett. 2017;14:4613-4618.
Gong H, Chen X, Jin Y, et al. Expression of ARHGAP10 correlates with prognosis of prostate cancer. Int J Clin Exp Pathol. 2019;12:3839-3846.
Li Y, Zeng B, Li Y, Zhang C, Ren G. Downregulated expression of ARHGAP10 correlates with advanced stage and high Ki-67 index in breast cancer. PeerJ. 2019;7:e7431.
Wang J, Liu D, Gu Y, et al. Potential prognostic markers and significant lncRNA-mRNA co-expression pairs in laryngeal squamous cell carcinoma. Open Life Sci. 2021;16:544-557.
Heppt MV, Gebhardt C, Hassel JC, et al. Long-term management of advanced basal cell carcinoma: current challenges and future perspectives. Cancers (Basel). 2022;19:4547.
Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848-857.
Tran DDH, Koch A, Allister A, et al. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP). Cell Signal. 2016;28:1872-1880.
Kiianitsa K, Zhang Y, Maizels N. Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1. DNA Repair (Amst). 2020;96:102977.
Stanoszek LM, Wang GY, Harms PW. Histologic mimics of basal cell carcinoma. Arch Pathol Lab Med. 2017;141:1490-1502.